Immix Biopharma Stock Today

IMMX Stock  USD 2.01  0.10  4.74%   

Performance

2 of 100

 
Weak
 
Strong
Weak

Odds Of Distress

Less than 36

 
High
 
Low
Below Average
Immix Biopharma is trading at 2.01 as of the 3rd of December 2024; that is 4.74 percent decrease since the beginning of the trading day. The stock's open price was 2.11. Immix Biopharma has about a 36 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Immix Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of November 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of December 2021
Category
Healthcare
Classification
Health Care
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company was incorporated in 2012 and is headquartered in Los Angeles, California. The company has 27.51 M outstanding shares of which 400.7 K shares are currently shorted by private and institutional investors with about 2.94 trading days to cover. More on Immix Biopharma
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Immix Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
Total Current Liabilities2.4 M3.7 M
Way Down
Slightly volatile
Total Assets12 M19.9 M
Way Down
Slightly volatile
Total Current Assets12 M19.8 M
Way Down
Slightly volatile
Debt Levels
Immix Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immix Biopharma's financial leverage. It provides some insight into what part of Immix Biopharma's total assets is financed by creditors.
Liquidity
Immix Biopharma currently holds 3.72 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Immix Biopharma has a current ratio of 19.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Immix Biopharma's use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

54,693.45
Immix Biopharma (IMMX) is traded on NASDAQ Exchange in USA. It is located in 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064 and employs 14 people. Immix Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.04 M. Immix Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.51 M outstanding shares of which 400.7 K shares are currently shorted by private and institutional investors with about 2.94 trading days to cover. Immix Biopharma currently holds about 18.4 M in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32.
Check Immix Biopharma Probability Of Bankruptcy
Ownership Allocation
Immix Biopharma has a total of 27.51 Million outstanding shares. Immix Biopharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immix Ownership Details

Immix Stock Institutional Holders

InstituionRecorded OnShares
Fny Investment Advisers, Llc2024-06-30
32.5 K
Invst Llc2024-06-30
27 K
Commonwealth Equity Services Inc2024-06-30
26.1 K
Tritonpoint Wealth Llc2024-09-30
24.5 K
Millennium Management Llc2024-09-30
21.5 K
Blackrock Inc2024-06-30
13.5 K
The Colony Group Llc2024-09-30
11.9 K
Old National Bancorp2024-09-30
10 K
Ubs Group Ag2024-09-30
6.1 K
Aigh Capital Management, Llc2024-09-30
1.1 M
Bleichroeder Lp2024-09-30
850 K
View Immix Biopharma Diagnostics

Immix Biopharma Historical Income Statement

At this time, Immix Biopharma's Net Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 7.8 M in 2024, whereas Tax Provision is likely to drop slightly above 12.5 K in 2024. View More Fundamentals

Immix Stock Against Markets

Immix Biopharma Corporate Management

JD MBACoFounderProfile
David MarksChief TherapyProfile
Gabriel BACFO DirectorProfile
Gerhard BauerHead ManufacturingProfile
MD FFPMChief DevelopmentProfile
Nandan BSManufacturing ChemistryProfile
MBA MDChairman CoFounderProfile

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.